The Department of Defense is offering the Alcohol and Substance Use Disorders Consortium Grant to advance pharmacotherapies for substance use disorders.

The FY24 ASUDRP CA supports the establishment of a Consortium whose purpose is to identify, evaluate, and advance pharmacotherapies for alcohol, opioid, and other substance use disorders, with an emphasis on other co-occurring mental health conditions, through rigorous, collaborative research efforts that translate basic knowledge and early-stage clinical products into evidence-based treatments. The goal of this research is to maximize functioning and quality of life for Service Members, their Families, Veterans, and the American public.

The proposed research must be relevant to Service Members, Veterans, military beneficiaries, and/or the American public.

Each individual organization must apply to this program announcement as a Consortium Management Core (CMC) by means of a single application, and may also serve as a future research and/or trial site. The CMC will be responsible for coordinating with the Consortium Steering Committee (CSC) and Consortium Executive Committee (CEC) to prioritize, propose, conduct, and analyze basic research and clinical trials, and developing a roadmap to translate basic science knowledge into evidence-based treatments for ASUD. Clinical trials that include military and Veteran populations are encouraged.